Diabetes mellitus and heart failure
Authors:
Ján Murín; František Mikla; Soňa Kiňová
Authors‘ workplace:
I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in:
Forum Diab 2016; 5(3): 137-141
Category:
Topic
Overview
Diabetes mellitus and heart failure are both diseases with an epidemic presence. In 70ties there were about 3.5 % of diabetics in our country and today it is about 7 %, but we have about 12.5 % of prediabetics. Prevalence of heart failure is nowadays about 1.5–2.0 %, but in elderly people (≥ 65 years) it is about 10 %. We have some risk factors of heart failure I diabetics: severe hypertension, hyperglycemia, dyslipidemia, diabetic cardiomyopathy, renal dysfunction, ischemic heart disease and obesity with metabolic syndrome. We distinguish two types of heart failure, but a typical type in diabetics is a “diastolic dysfunction” with dysfunction of relaxation of left ventricle. Researchers from Netherland discovered that about a quarter of diabetics suffer a symptomatic and another quarter an asymptomatic heart failure. There is some improvement in the treatment of heart failure in diabetics, and a successful drug is empagliflosine. Also in the inhibition of renin-angiotensin–aldosterone system is a new successful drug, ARNI (angiotensin receptor neprilysine inhibitor) with an ambition to replace ACE inhibitors and sartans. There is an improvement of heart failure treatment in diabetics.
Key words:
type 2 diabetes – heart failure – risk factors – ARNI – empagliflosine
Sources
1. Fillipitos G, Khan SS, Ambrossy AP et al. International REgistry to assess medical Practice with lOgitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail 2015; 17(5): 527–533. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.262. Epub 2015 Mar 10>.
2. Chen J, Normand S-LT, Wang Y et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 2011; 306(15): 1669–1678. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2011.1474>.
3. MacDonald MR, Eurich DT, Majumdar SR et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010; 33(6): 1213–1218. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–2227>.
4. Mokáň M, Galajda P, Prídavková D et al. Prevalencia diabetes mellitus a metabolického syndrómu na Slovensku. Diabetes a obezita 2006; 6(12): 10–17.
5. Pernický M, Murín J. Pacienti v Ústavnej pohotovostnej službe na Internej klinike. Cardiology 2010; 19: 201–204.
6. Levy D, Larson MG, Vasan RS et al. The progresssion from hypertension to congestive heart failure. JAMA 1996; 275(20): 1557–1562.
7. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35(6): 1628–1637.
8. Damman K, Valente MAE, Voors AA et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35(7): 455–469.
9. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012; 14(8): 803–869. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfs105>.
10. Nichols GA, Hillier TA, Erbey JR et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24(9): 1614–1619.
11. Aguilar D, Solomon SD, Kober L et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110(2): 1572–1578.
12. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010; 16(12): 971–979. Erratum in J Card Fail. 2011; 17(3): 264.
13. Saunders J, Mathewkutty S, Drazner MH et al. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanism. Herz 2008; 33(3): 184–190. Dostupné z DOI: <http://dx.doi.org/10.1007/s00059–008–3115–3>.
14. Lindsey JB, Cipollone F, Abdullah SM et al. Receptor for advanced glycation end-poducts (RAGE). Cardiovascular implications. Diab Vasc Dis Res 2009; 6(1): 7–14. Dostupné z DOI: <http://dx.doi.org/10.3132/dvdr.2009.002>.
15. Tjeerdsma G, Szabó BM, van Wijk LM et al. Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on beta-blockade. Eur J Heart Fail 2001; 3(1): 33–39.
16. Marazzi G, Wajngarten M, Vitale C et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007; 120(1): 79–84.
17. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016. pii: ehw210. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw210>.
18. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013; 34(39): 3035–3087. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht108>.
19. Khera A, McGuire DK. Management of diabetic dyslipidemia: need for reappraisal of the goals. Am J Cardiovasc Drugs 2005; 5(2): 83–91.
20. Kenchaiah S, Evans JC, Levy D et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368(9535): 581–588.
21. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 18(8): 891–975.
22. Butler J, Fonarow GC, Zile MR et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart fail 2014; 2(2): 97–112. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2013.10.006>.
23. Boonman-de Winter LJM, Rutten FH, Cramer MJM et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012; 55: 2154–2162. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–012–2579–0>.
24. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl Med 2015; 373(22): 2117–2128. <http://dx.doi.org/10.1056/NEJMoa1504720>.
25. Musetti C, Quaglia M, Stratta P. A nephrologist point of view on sodium – glucose linked trans-porter-2 inhibitors. Kidney Int 2014; 85(5): 1243. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2014.42>.
26. Marso SP, Daniels GH, Brown-Frandsen et al. Liraglutide and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med 2016; 375 (4): 311–22. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
27. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993–1004. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1409077>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2016 Issue 3
Most read in this issue
- Diabetes mellitus and secondary immunodeficiency
- Chronic obstructive pulmonary disease, metabolic syndrome and diabetes mellitus
- An infection of the urogenital tract in female patients with diabetes
- Assessment of the development of head and neck infections – comparison of cohorts of patients with and without diabetes mellitus